Regulation in S phase by E2F

Cell Cycle

Volumn 3, Issue 9, 2004, Pages 1089-1092

  Pardee, Arthur B ^a,d   Li, Chiang J ^b   Reddy, G Prem Veer ^c  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b ARQULE INC   (United States)

^c HENRY FORD HEALTH SYSTEM   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEOXYNUCLEOTIDE TRIPHOSPHATE; DEOXYRIBONUCLEOTIDE; GROWTH FACTOR; THYMIDINE TRIPHOSPHATE; TRANSCRIPTION FACTOR E2F; TRANSCRIPTION FACTOR E2F1; UNCLASSIFIED DRUG;

ALLOSTERISM; APOPTOSIS; CARCINOGENESIS; CELL CYCLE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL GROWTH; DNA SYNTHESIS; FEEDBACK SYSTEM; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; PROTEIN DEGRADATION; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION;

EID: 13944249144     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.3.9.1143     Document Type: Review

References (77)

1. Angus SP, Wheeler LJ, Ranmal SA, Zhang X, Markey MP, Mathews CK, et al. Retinoblastoma tumor suppressor targets dNTP metabolism to regulate DNA replication. J Biol Chem 2002; 277:44376-84.
2. Pardee AB, Reddy GP. Beginnings of feedback inhibition, allostery, and multi-protein complexes. Gene 2003; 321:17-23.
3. 1/S-regulated E2F-containing protein complexes bind to the mouse thymidine kinase gene promoter. J Biol Chem 1994; 269:1306-13.
4. Sears RC, Nevins JR. Signaling networks that link cell proliferation and cell fate. J Biol Chem 2002; 277:11617-20.
5. 1/S transition and their response to DNA damage. FEBS Lett 2001; 490:117-22.
6. Hitchens MR, Robbins PD. The role of the transcription factor DP in apoptosis. Apoptosis 2003; 8:461-8.
7. Harbour JW, Dean DC. Corepressors and retinoblastoma protein function. Curr Top Microbiol Immunol 2001; 254:137-44.
8. Morris EJ, Dyson NJ. Retinoblastoma protein partners. Adv Cancer Res 2001; 82:1-54.
9. Trimarchi JM, Lees JA. Sibling rivalry in the E2F family. Nat Rev Mol Cell Biol 2002; 3:11-20.
10. Stevens C, La Thangue NB. E2F and cell cycle control: A double-edged sword. Arch Biochem Biophys 2003; 412:157-69.
11. Gao G, Bracken AP, Butkard K, Pasini D, Classon M, Attwooll C, et al. NPAT expression is regulated by E2F and is essential for cell cycle progression. Mol Cell Biol 2003; 23:2821-33.
12. Takahashi Y, Rayman JB, Dynlacht BD. Analysis of promoter binding by the E2F and pRB families in vivo: Distinct E2F proteins mediate activation and repression. Genes Dev 2000; 14:804-16.
13. Yamasaki L. Balancing proliferation and apoptosis in vivo: The Goldilocks theory of E2F/DP action. Biochim Biophys Acta 1999; 1423:M9-15.
14. Oliver FJ, Collins MK, Lopez-Rivas A. dNTP pools imbalance as a signal to initiate apoptosis. Experientia 1996; 52:995-1000.
15. Ahmad SI, Kirk SH, Eisenstark A. Thymine metabolism and thymineless death in prokaryotes and eukaryotes. Annu Rev Microbiol 1998; 52:591-625.
16. Ladner RD. The role of dUTPase and uracil-DNA repair in cancer chemotherapy. Curr Protein Pept Sci 2001; 2:361-70.
17. Yoshioka A, Tanaka S, Hiraoka O, Koyama Y, Hirota Y, Ayusawa D, et al. Deoxyribonucleoside triphosphate imbalance. 5-Fluorodeoxyuridine-induced DNA double strand breaks in mouse FM3A cells and the mechanism of cell death. J Biol Chem 1987; 262:8235-41.
18. Huang M, Kozlowski P, Collins M, Wang Y, Haystead TA, Graves LM. Caspase-dependent cleavage of carbamoyl phosphate synthetase II during apoptosis. Mol Pharmacol 2002; 61:569-77.
19. Zhong W, Feng H, Santiago FE, Kipreos ET. CUL-4 ubiquitin ligase maintains genome stability by restraining DNA-replication licensing. Nature 2003; 423:885-9.
20. Chabes AL, Pfleger CM, Kirschner MW, Thelander L. Mouse ribonucleotide reductase R2 protein: A new target for anaphase-promoting complex-Cdh1-mediated proteolysis. Proc Natl Acad Sci USA 2003; 100:3925-9.
21. Banerjee D, Schnieders B, Fu JZ, Adhikari D, Zhao SC, Bertino JR. Role of E2F-1 in chemosensitivity. Cancer Res 1998; 58:4292-6.
22. Wilkinson YA, McKenna PG. The effects of thymidine on deoxyribonucleotide pool levels, cytotoxicity and mutation induction in Friend mouse erythroleukaemia cells. Leuk Res 1989; 13:615-20.
23. Wang AJ, Li CJ, Reddy PV, Pardee AB. dTTP depletion, E2F-1 elevation and cancer chemotherapy. 2004; In preperation.
24. Johnson DG. The paradox of E2F1: Oncogene and tumor suppressor gene. Mol Carcinog 2000; 27:151-7.
25. Kaelin Jr WG. E2F1 as a target: Promoter-driven suicide and small molecule modulators. Cancer Biol Ther 2003; 2:548-54.
26. Vermeulen K, Van Bockstaele DR, Berneman ZN. The cell cycle: A review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif 2003; 36:131-49.
27. Mundle SD, Saberwal G. Evolving intricacies and implications of E2F1 regulation. FASEB J 2003; 17:569-74.
28. Heldin CH. Signal transduction: Multiple pathways, multiple options for therapy. Stem Cells 2001; 19:295-303.
29. Wu X, Levine AJ. p53 and E2F-1 cooperate to mediate apoptosis. Proc Natl Acad Sci USA 1994; 91:3602-6.
30. Shan B, Farmer AA, Lee WH. The molecular basis of E2F-1/DP-1-induced S-phase entry and apoptosis. Cell Growth Differ 1996; 7:689-97.
31. Almasan A, Yin Y, Kelly RE, Lee EY, Bradley A, Li W, et al. Deficiency of retinoblastoma protein leads to inappropriate S-phase entry, activation of E2F-responsive genes, and apoptosis. Proc Natl Acad Sci USA 1995; 92:5436-40.
32. Ma Y, Cress WD, Haura EB. Flavopiridol-induced apoptosis is mediated through up-regulation of E2F1 and repression of Mcl-1. Mol Cancer Ther 2003; 2:73-81.
33. Hsieh JK, Yap D, O'Connor DJ, Fogal V, Fallis L, Chan F, et al. Novel function of the cyclin A binding site of E2F in regulating p53-induced apoptosis in response to DNA damage. Mol Cell Biol 2002; 22:78-93.
34. Krek W, Xu G, Livingston DM. Cyclin A-kinase regulation of E2F-1 DNA binding function undetlies suppression of an S phase checkpoint. Cell 1995; 83:1149-58.
35. Ginsberg D. E2F1 pathways to apoptosis. FEBS Lett 2002; 529:122-5.
36. Vousden KH, Lu X. Live or let die: The cell's response to p53. Nature Rev Cancer 2002; 2:6594-604.
37. Oren M, Damalas A, Gottlieb T, Michael D, Taplick J, Leal JF, et al. Regulation of p53: Intricate loops and delicate balances. Ann NY Acad Sci 2002; 973:374-83.
38. Coqueret O. New roles for p21 and p27 cell-cycle inhibitors: A function for each cell compartment? Trends Cell Biol 2003; 13:65-70. w.
39. Lozano G, Elledge SJ. p53 sends nucleotides to repair DNA. Nature 2000; 404:24-5.
40. Johnson DG, Cress WD, Jakoi L, Nevins JR. Oncogenic capacity of the E2F1 gene. Proc Natl Acad Sci USA 1994; 91:12823-7.
41. Shen WH, Yin Y, Broussard SR, McCusker RH, Freund GG, Dantzer R, et al. Tumor necrosis factor alpha inhibits cyclin A expression and retinoblastoma hyperphosphorylation triggered by insulin-like growth factor-I induction of new E2F-1 synthesis. J Biol Chem 2004; 279:7438-46.
42. Adams MR, Sears R, Nuckolls F, Leone G, Nevins JR. Complex transcriptional regulatory mechanisms control expression of the E2F3 locus. Mol Cell Biol 2000; 20:3633-9.
43. Neuman E, Flemington EK, Sellers WR, Kaelin Jr WG. Transcription of the E2F-1 gene is rendered cell cycle dependent by E2F DNA-binding sites within its promoter. Mol Cell Biol 1994; 14:6607-15.
44. Hsiao KM, McMahon SL, Farnham PJ. Multiple DNA elements are required for the growth regulation of the mouse E2F1 promoter. Genes Dev 1994; 8:1526-37.
45. 1 restriction point fails to halt cell cycle progression. Oncogene 1997; 15:337-45.
46. Hateboer G, Kerkhoven RM, Shvarts A, Bernards R, Beijersbergen RL. Degradation of E2F by the ubiquitin-proteasome pathway. Regulation by retinoblastoma family proteins and adenovirus transforming proteins. Genes Dev 1996; 10:2960-70.
47. Wang C, Fu M, Mani S, Wadler S, Senderowicz MA, Pestell RG. Histone acerylation and the cell-cycle in cancer. Front Biosci 2001; 6:D610-29.
48. Chabes A, Thelander L. Controlled protein degradation regulates ribonucleotide reductase activity in prolferating mammalian cells during the normal cell cycle and in respose to DNA damage and replication blocks. J Biol Chem 2000; 275:17747-53.
49. Skowyra D, Craig K, Tylers M, Elledge SJ, Harper JW. F-box proteins are receptors that recruit phosphorylated substrates to the SCF ubiquitin-ligase complex. Cell 1997; 91:209-17.
50. Aleem E, Berthet C, Kaldis P. Cdk2 as a master of S phase entry. Cell Cycle 2004; 3:35-7.
51. Strausfeld UP, Howell M, Descombes P, Chevalier S, Rempel RE, Adamczewski J, et al. Both cyclin A and cyclin E have S-phase promoting (SPF) activity in Xenopus egg extracts. J Cell Sci 1996; 109:1555-63.
52. Jaumot M, Grana X, Giordano A, Reddy PV, Agell N, Bachs O. Cyclin/cdk2 complexes in the nucleus of HeLa cells. Biochem Biophys Res Commun 1994; 203:1527-34.
53. Cardoso MC, Leonhardt H, Nadal-Ginard B. Reversal of terminal differentiation and control of DNA replication: Cyclin A and Cdk2 specifically localize at subnuclear sites of DNA replication. Cell 1993; 74:979-92.
54. Dynlacht BD, Moberg K, Lees JA, Harlow E, Zhu L. Specific regulation of E2F family members by cyclin-dependent kinases. Mol Cell Biol 1997; 17:3867-75.
55. Coulonval K, Bockstaele L, Paternot S, Roger PP. Phosphoylations of cyclin-dependent kinase 2 revisited using two-dimensional gel electrophoresis. J Biol Chem 2003; 278:52052-60.
56. Ohta T, Xiong Y. Phosporylation and SKP1-independent in vitro ubiqutination of E2F1 by multiple ROC-cullin ligases. Cancer Res 2001; 61:1347-53.
57. Krek W, Ewen ME, Shirodkar S, Arany Z, Kaelin Jr WG, Livingston DM. Negative regulation of the growth-promoting transcription factor E2F-1 by a stably bound cyclin A-dependent protein kinase. Cell 1994; 78:161-72.
58. Yam CH, Fung TK, Poon RY. Cyclin A in cell cycle control and cancer. Cell Mol Life Sci 2002; 59:1317-26.
59. Lin WC, Lin FT, Nevins JR. Selective induction of E2F1 in response to DNA damage, mediated by ATM-dependent phosphorylation. Genes Dev 2001; 15:1833-44.
60. Wang S, Nath N, Minden A, Chellappan S. Regulation of Rb and E2F by signal transduction cascades: Divergent effects of JNK1 and p38 kinases. EMBO J 1999; 18:1559-70.
61. Hsueh CT, Wu YC, Schwartz GK. UCN-01 suppresses E2F-1 mediated by ubiquitin-proteasome-dependent degradation. Clin Cancer Res 2001; 7:669-74.
62. Martelli F, Hamilton T, Silver DP, Sharpless NE, Bardeesy N, Grossman SR. p19ARF targets certain E2F species for degradation. Proc Natl Acad Sci USA 2001; 98:4455-60.
63. Hershko A, Ciechanover A. The ubiquitin system. Annu Rev Biochem 1998; 67:425-79.
64. Bloom J, Pagano M. Deregulated degradation of the cdk inhibitor p27 and malignant transformation. Semin Cancer Biol 2003; 13:41-7.
65. Marti A, Wirbelauer C, Scheffner M, Krek W. Interaction between ubiquitin-protein ligase SCFSKP2 and E2F-1 underlies the regulation of E2F-1 degradation. Nat Cell Biol 1999; 114-9.
66. Yokoi S, Yasui K, Iizasa T, Takahashi T, Fujisawa T, Inazawa J. Down-regulation of SKP2 induces apoptosis in lung-cancer cells. Cancer Sci 2003; 94:344-9.
67. Farhana L, Dawson M, Rishi AK, Zhang Y, Van Buren E, Trivedi C, et al. Cyclin B and E2F-1 expression in prostate carcinoma cells treated with the novel retinoid CD437 are regulated by the ubiquitin-mediated pathway. Cancer Res 2002; 1:3842-9.
68. Bornstein G, Bloom J, Sitry-Shevah D, Nakayama K, Pagano M, Hershko A. Role of the SCFSkp2 ubiquitin ligase in the degradation of p21Cip1 in S phase. J Biol Chem 2003; 278:25752-7.
69. Kisselev AF, Goldberg AL. Proteasome inhibitors: From research tool to drug candidates. Chem Biol 2001; 8:739-58.
70. Kazi A, Hill R, Long TE, Kuhn DJ, Turos E, Dou QP. Novel N-thiolated beta-lactam antibiotics selectively induce apoptosis in human tumor and transformed, but not normal or nontransformed, cells. Biochem Pharmacol 2004; 67:365-74.
71. Yano M, Mori S, Kido H. Intrinsic nucleoside diphosphate kinase-like activity is a novel function of the 20 S proteasome. J Biol Chem 1999; 274:34375-82.
72. Halaban R. The Rb/E2F pathway and cancer. Hum Mol Genet 2000; 10:699-703.
73. Phillips AC, Vousden KH. E2F-1 induced apoptosis. Apoptosis 2001; 6:173-82.
74. Chen W, Lee J, Cho SY, Fine HA. Proteasome-mediated destruction of the cyclin a/cyclin-dependent kinase 2 complex suppresses tumor cell growth in vitro and in vivo. Cancer Res 2004; 64:3949-57.
75. Chen YN, Sharma SK, Ramsey TM, Jiang L, Martin MS, Baker K, et al. Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists. Proc Natl Acad Sci USA 1999; 96:4325-9.
76. Blagosklonny MV, Pardee AB. Conceptual biology: Unearthing the gems. Nature 2002; 416:373.
77. Jasny BR, Ray LB. Life and the art of networks. Science 2003; 301:1863.